Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
CFO resigned
Consulting agrmnt
Director departure
Appointed director
ENLIVEN MARKETING TECHNOLOGIES CORP (ENLV) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/22/2021 GN Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra™ in Combination with Immune Checkpoint Inhibitors
03/09/2021 GN Enlivex Announces Upcoming Virtual Investor Conference Participations
03/01/2021 GN Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors
02/16/2021 GN Enlivex Announces Issuance of New U.S. Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis and GvHD Using Allocetra Immunotherapy
02/12/2021 GN Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
02/09/2021 GN Enlivex Increases Previously Announced Bought Deal Offering to Approximately $46.0 Million of Ordinary Shares
02/09/2021 GN Enlivex Announces $10 Million Bought Deal Offering of Ordinary Shares
02/03/2021 GN Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update
01/11/2021 GN Enlivex to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
12/21/2020 GN Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
12/07/2020 GN Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy
12/03/2020 GN Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
11/18/2020 GN Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra
11/17/2020 GN Enlivex Appoints Former ArQule, Inc. Executive Dr. Brian Schwartz to the Company's Board of Directors
11/11/2020 GN Enlivex to Present Schedule for Sepsis, COVID-19 and Solid Cancer Programs at H.C. Wainwright's 6th Annual Israel Conference
11/03/2020 GN Enlivex: Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis Patients
10/22/2020 GN Enlivex Reports Dosing of First Two Patients in Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
10/13/2020 GN Enlivex: After Expedited Review, Israeli Ministry of Health Authorizes Initiation of Phase II Clinical Trial Evaluating Allocetra in COVID-19 Severe and Critical Patients
10/01/2020 GN Enlivex Reports Positive Allocetra Trial Results in COVID-19 Patients in Severe/Critical Condition
08/10/2020 GN Enlivex Announces Dosing of First Patient in Clinical Trial of Allocetra in COVID-19 Patients with Severe Illness Respiratory Failure
07/20/2020 GN Enlivex Announces a new publication “Apoptotic cell therapy for cytokine storm associated with acute severe sepsis?? in Cell Death & Disease, a Nature Research Journal
06/18/2020 GN Enlivex Announces Allowance of New Japanese Patent Application Covering ALLOCETRA Immunotherapy
05/07/2020 GN Enlivex Announces Initiation of Multi-Center Phase II Investigator-Initiated Clinical Trial of Allocetra in COVID-19 Patients
04/13/2020 GN Enlivex Selected by the Israel Innovation Authority to Receive $1.5 Million Grant to Fund COVID-19 and Sepsis Clinical Trials
03/18/2020 GN Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis
03/09/2020 GN Israel Patent Office Grants New Patent Covering Enlivex's Allocetra Immunotherapy Treatment
03/05/2020 GN Enlivex Therapeutics Closes $16.75 Million Registered Direct Offering
03/02/2020 GN Enlivex Therapeutics Announces $16.75 Million Registered Direct Offering
02/26/2020 GN Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering
02/24/2020 GN Enlivex Therapeutics Announces $8.0 Million Registered Direct Offering
02/24/2020 GN Enlivex Therapeutics Announces Plan for Increased Production Capacity of AllocetraTM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure
02/20/2020 GN Data On Enlivex's Allocetra-OTS Immunotherapy for Peritoneal Solid Tumors and for Prevention of GvHD Selected for Presentation at the Transplantation & Cellular Therapy Meetings Conference (TCT) in Orlando, Florida
11/21/2019 GN Enlivex Therapeutics Ltd. Announces Withdrawal of Proposed Offering of Ordinary Shares
11/20/2019 GN Enlivex Therapeutics Ltd. Announces Proposed Offering of Ordinary Shares
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy